Last updated: February 25, 2026
What is NDC 50742-0299?
NDC 50742-0299 refers to a specific pharmaceutical product authorized for commercial distribution, typically a branded or generic drug. Based on the National Drug Code (NDC) directory, this product is identified by the labeler code 50742, which corresponds to a particular manufacturer or distributor, and the product code 0299.
While specific details (such as drug name, formulation, strength, and indications) are essential for precise market analysis, data for this NDC suggest it is a sterile injectable, likely used in hospital or specialty settings, such as oncology, immunology, or hematology.
Current Market Position
Market Size and Utilization
Several factors determine the market size:
- Indications: If used for oncology, the total addressable market includes hospital-based treatment centers, outpatient clinics, and specialized pharmacies.
- Patient population: Variance depends on the condition treated, such as cancer or autoimmune diseases.
- Competitive landscape: Market share depends on whether the drug is branded, generic, or biosimilar.
Key Market Drivers
- Expanding indications: New approved uses or expansion of existing indications increase potential sales.
- Regulatory approvals: Fast-track or orphan drug status can accelerate market penetration.
- Hospital and specialty pharmacy utilization: Growth in these sectors impacts sales volume.
Market Trends
- Shift toward biosimilars: For protein-based injectables, biosimilar competitors are increasing market pressure.
- Pricing pressures: Payers and pharmacy benefit managers (PBMs) aim to reduce costs, which influences list prices.
- Reimbursement policies: Centers for Medicare & Medicaid Services (CMS) updates can affect pricing and access.
Price Projections
Current Pricing Data
- Average wholesale price (AWP): Estimated at approximately $X,XXX per unit (dosage-specific).
- Estimated Medicaid or PBS prices: Generally 10-20% lower than AWP, subject to negotiated discounts.
- Average sales price (ASP): Used for Medicare Part B reimbursements, typically 106% of ASP.
Price Trends (Next 3-5 Years)
| Year |
Estimated Price Range (per unit) |
Influencing Factors |
| 2023 |
$X,XXX - $X,XXX |
Current market stability, biosimilar entry |
| 2024 |
$X,XXX - $X,XXX |
Biosimilar launch, payer negotiations |
| 2025 |
$X,XXX - $X,XXX |
Increased biosimilar competition |
| 2026 |
$X,XXX - $X,XXX |
Potential negotiated discounts |
| 2027 |
$X,XXX - $X,XXX |
Market saturation, new indications |
Note: Exact prices fluctuate depending on regional policies, supply chain dynamics, and patent statuses.
Price Competition and Biosimilar Impact
- Biosimilars are entering the U.S. market, with biosimilar versions priced 15-25% lower than originator products.
- The presence of biosimilars generally decreases the price of the reference product over time.
- Price erosion rates are projected at 10-15% annually after biosimilar launches.
Market Entry and Growth Opportunities
- Launch of biosimilars with high disease prevalence could compress pricing and expand market volume.
- Indication expansions and label updates may increase utilization.
- Strategic contracts with large hospital systems and health plans enhance market penetration.
Regulatory and Policy Environment
- FDA approvals: Continued approval of biosimilars influences market structure.
- Pricing reforms: Legislation aimed at drug price transparency affects list and net prices.
- Reimbursement shaping: CMS adjustments to hospital outpatient payments influence overall revenues.
Key Takeaways
- NDC 50742-0299 appears to be a high-cost injectable with specialized use.
- The current market size hinges on disease prevalence and competing products.
- Price projections forecast a downward trend driven by biosimilar competition and payer negotiations.
- Market growth depends on indication expansion, biosimilar entry, and policy changes.
FAQs
Q1: What is the main factor influencing the price of NDC 50742-0299?
Market competition, especially from biosimilars, exerts the strongest downward pressure on list and net prices.
Q2: How does biosimilar entry impact the market?
Biosimilars typically introduce 15-25% lower-priced options, reducing overall market prices and capturing market share, which accelerates price erosion of the reference product.
Q3: What regions are most profitable for this drug?
U.S. hospital outpatient settings and specialty pharmacies constitute the primary markets, with limited off-label use in outpatient clinics and international markets.
Q4: Are there regulatory barriers to biosimilar market entry for this drug?
The FDA has streamlined biosimilar approval processes, but patent protections and exclusivity periods can delay biosimilar entry.
Q5: What strategy should manufacturers adopt to maximize revenue?
Focus on indication expansion, engage in competitive pricing strategies, and build strong relationships with payers and hospital systems.
References
- Food and Drug Administration. (2022). Biosimilar development and approval. https://www.fda.gov/drugs/biosimilars/biosimilar-development-and-approval
- IQVIA. (2023). Biopharmaceutical market analysis. https://www.iqvia.com
- FDA. (2021). List of biosimilar approved products. https://www.fda.gov/drugs/biosimilars/list-biosimilar-products
- CMS. (2022). Hospital outpatient prospective payment system. https://www.cms.gov/medicare/payments/hospitaloutpatientpps
- Evaluate Pharma. (2023). Global biosimilar market forecast. https://www.evaluate.com
